Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2009
Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancerJoseph A Sparano, Stacy Moulder, Aslamuzzaman Kazi, et al.
NPJ Breast Cancer|January 6, 2026
Racial disparity in pro-metastatic tumor microenvironment in treatment naïve breast cancerPriyanka Parmar, Burcu Karadal-Ferrena, Suryansh Shukla, et al.
Journal of the National Cancer Institute|December 28, 2020
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working GroupTorsten O Nielsen, Samuel C Y Leung, David L Rimm, et al.
Seminars in Cancer Biology|October 13, 2017
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast CancerMaria Vittoria Dieci, Nina Radosevic-Robin, Susan Fineberg, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 21, 2015
An international study to increase concordance in Ki67 scoringMei-Yin C Polley, Samuel C Y Leung, Dongxia Gao, et al.
NPJ Breast Cancer|July 20, 2017
Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaborationSamuel C Y Leung, Torsten O Nielsen, Lila Zabaglo, et al.
Histopathology|April 25, 2019
Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaborationSamuel C Y Leung, Torsten O Nielsen, Lila A Zabaglo, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 21, 2022
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional studyBalazs Acs, Samuel C Y Leung, Kelley M Kidwell, et al.
NPJ Breast Cancer|December 2, 2021
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working GroupKhalid El Bairi, Harry R Haynes, Elizabeth Blackley, et al.
The Journal of Pathology|March 5, 2020
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practicePaula I Gonzalez-Ericsson, Elisabeth S Stovgaard, Luz F Sua, et al.
Pageof 6